Prophase Labs Stock Analysis

ProPhase Stock Analysis Notes

The company has price-to-book ratio of 0.22. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. ProPhase Labs recorded a loss per share of 15.28. The entity last dividend was issued on the 24th of May 2022. The firm had 1:10 split on the 22nd of December 2025. ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over the counter consumer healthcare products and dietary supplements in the United States. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York. Prophase Labs operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 129 people. To find out more about ProPhase Labs contact Ted Karkus at 215 345 0919 or learn more at https://www.prophaselabs.com.

ProPhase Labs Investment Alerts

ProPhase Labs Upcoming and Recent Events

ProPhase Largest EPS Surprises

View All Earnings Estimates

ProPhase Stock Institutional Investors

Note, although ProPhase Labs' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

ProPhase Market Capitalization

The company currently falls under 'Nano-Cap' category with a current market capitalization of 1.52 M.

ProPhase Profitablity

Management Efficiency

ProPhase Labs has return on total asset (ROA) of (0.235) % which means that it has lost $0.235 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.2034) %, meaning that it created substantial loss on money invested by shareholders. ProPhase Labs' management efficiency ratios could be used to measure how well ProPhase Labs manages its routine affairs as well as how well it operates its assets and liabilities. The ProPhase Labs' current Return On Tangible Assets is estimated to increase to -1.21. The ProPhase Labs' current Return On Capital Employed is estimated to increase to -1.36. As of now, ProPhase Labs' Intangible Assets are increasing as compared to previous years. The ProPhase Labs' current Other Assets is estimated to increase to about 1.6 M, while Total Assets are projected to decrease to under 36.6 M.

Technical Drivers

As of the 6th of January, ProPhase Labs holds the Coefficient Of Variation of (267.44), risk adjusted performance of (0.26), and Variance of 80.26. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of ProPhase Labs, as well as the relationship between them.

ProPhase Labs Price Movement Analysis

ProPhase Labs Insider Trading Activities

ProPhase Labs Outstanding Bonds

ProPhase Labs Predictive Daily Indicators

ProPhase Labs Forecast Models

ProPhase Labs' time-series forecasting models are one of many ProPhase Labs' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary ProPhase Labs' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

ProPhase Labs Bond Ratings

ProPhase Labs financial ratings play a critical role in determining how much ProPhase Labs have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for ProPhase Labs' borrowing costs.

ProPhase Labs Debt to Cash Allocation

ProPhase Labs currently holds 24.57 M in liabilities with Debt to Equity (D/E) ratio of 0.19, which may suggest the company is not taking enough advantage from borrowing. ProPhase Labs has a current ratio of 4.12, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about ProPhase Labs' use of debt, we should always consider it together with its cash and equity.

ProPhase Labs Total Assets Over Time

ProPhase Labs Assets Financed by Debt

The debt-to-assets ratio shows the degree to which ProPhase Labs uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.

ProPhase Labs Debt Ratio

37.0

It feels like under 63% of ProPhase Labs' assets are financed through equity. Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the ProPhase Labs' operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of ProPhase Labs, which in turn will lower the firm's financial flexibility.

ProPhase Labs Corporate Bonds Issued

ProPhase Net Debt

Stock analysis is the technique used by a trader or investor to examine and evaluate how ProPhase Labs prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling ProPhase shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as ProPhase Labs. By using and applying ProPhase Stock analysis, traders can create a robust methodology for identifying ProPhase entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. ProPhase analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. ProPhase analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

ProPhase Labs stock analysis indicators help investors evaluate how ProPhase Labs stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading ProPhase Labs shares will generate the highest return on investment. By understating and applying ProPhase Labs stock analysis, traders can identify ProPhase Labs position entry and exit signals to maximize returns.

When running ProPhase Labs' price analysis, check to measure ProPhase Labs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ProPhase Labs is operating at the current time. Most of ProPhase Labs' value examination focuses on studying past and present price action to predict the probability of ProPhase Labs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ProPhase Labs' price. Additionally, you may evaluate how the addition of ProPhase Labs to your portfolios can decrease your overall portfolio volatility.